WO2014178383A1 - Diagnostic de la neutropénie fébrile par mesure de la présepsine - Google Patents

Diagnostic de la neutropénie fébrile par mesure de la présepsine Download PDF

Info

Publication number
WO2014178383A1
WO2014178383A1 PCT/JP2014/061897 JP2014061897W WO2014178383A1 WO 2014178383 A1 WO2014178383 A1 WO 2014178383A1 JP 2014061897 W JP2014061897 W JP 2014061897W WO 2014178383 A1 WO2014178383 A1 WO 2014178383A1
Authority
WO
WIPO (PCT)
Prior art keywords
scd14
patient
concentration
febrile neutropenia
cancer
Prior art date
Application number
PCT/JP2014/061897
Other languages
English (en)
Japanese (ja)
Inventor
博久 中前
秀男 康
Original Assignee
持田製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 持田製薬株式会社 filed Critical 持田製薬株式会社
Priority to JP2015514852A priority Critical patent/JP6445969B2/ja
Publication of WO2014178383A1 publication Critical patent/WO2014178383A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Definitions

  • the present invention relates to a method for detecting febrile neutropenia using sCD14-ST (also known as preceptin (registered trademark)) and a method for selecting a patient with febrile neutropenia to be administered with an antibiotic. .
  • Cancer patients are affected by the treatment of anticancer drugs and / or radiation therapy for cancer treatment and bone marrow transplantation pretreatment, such as damage to bone marrow and decrease in white blood cells.
  • cancer treatment and bone marrow transplantation pretreatment such as damage to bone marrow and decrease in white blood cells.
  • Non-Patent Document 1 Fever occurs at a frequency of 7-28%, breast cancer 2-34%, malignant lymphoma 18-48% (febrile neutropenia (FN) clinical practice guidelines: edited by the Japanese Society of Clinical Oncology, Issued by Nanedo, 2012 (hereinafter sometimes referred to as Non-Patent Document 1) Also, if fever occurs during neutropenia, it can sometimes become severely fatal, so ascertain the pathology as early as possible. It is said that it is necessary to start proper treatment.
  • the febrile neutropenia (hereinafter sometimes referred to as FN) disease name was proposed as a fever symptom during neutropenia, and FN guidelines were created in Japan in 1998.
  • Febrile neutropenia is a condition in which the neutrophil count is expected to be less than 500 / ⁇ L (500 / mm 3 ), or less than 1000 / ⁇ L within 48 hours and less than 500 / ⁇ L, and It is defined as a case where fever with an axilla temperature of 37.5 ° C. or higher (oral temperature of 38 ° C. or higher) occurs.
  • causes of fever of FN include fever caused by bacteria and fungi, drug fever, tumor fever and the like, and there is fever (unknown fever) whose cause is not specified after the fact.
  • the causative microorganism is identified by blood culture. Not only it takes 24 to 48 hours to determine, but the detection rate is reported to be 10% or less (Tamura Kazuo, Journal of Infectious Diseases) 80 (4): 358-365 2006).
  • Non-Patent Document 1 states that “the measurement of serum C-reactive protein (CRP) and procalcitonin (PCT) in FN is a secondary index for evaluating bacterial and fungal infections. However, it may not be the basis for antimicrobial treatment even if CRP and PCT are negative, because it may remain within the standard value in the initial stage of FN. " ing.
  • FN needs to grasp the pathological condition as soon as possible and start appropriate treatment, there is no appropriate biomarker for detecting the disease at the time of onset, and it is often impossible to identify the cause after onset There is a problem. Therefore, in FN, antibiotics are administered as empirical treatment (empiric treatment) even if the cause cannot be identified. Not only is it difficult to identify the cause of FN onset, but it is difficult to determine the cause and the risk of being fatal after the onset. Since it is often continued, it is considered that there are problems from the generation of resistant bacteria and medical economics.
  • Another problem is that elderly people and steroid-administered patients often have fever suppressed, and there is a problem that appropriate treatment such as administration of antibiotics cannot be taken and the disease becomes rapidly severe. Therefore, a detection method that can detect febrile neutropenia before or simultaneously with fever of neutropenia is desired.
  • cancer treatment may be interrupted due to side effects, and in order to obtain a sufficient effect of cancer treatment, it is necessary to appropriately understand and deal with side effects. Proper continuation is expected.
  • Patients who receive anti-cancer drugs and / or radiation are at high risk of causing bacteremia as a result of stomatitis, gastrointestinal mucosal damage, and skin and mucosal barrier breakdown resulting in bacterial invasion. Become. Tumor obstruction of the respiratory tract, gastrointestinal tract, bile duct, and urinary tract is also a risk of developing an infection.
  • the frequency of causing FN increases as the duration of neutropenia increases.
  • sCD14-ST soluble CD14 antigen subtype, also known as preceptin
  • sCD14-ST soluble CD14 antigen subtype, also known as preceptin
  • sCD14-ST is produced in the process of phagocytic cells phagocytosing and digesting foreign microorganisms and foreign substances, and in diseases such as arthritis where local autoimmune reactions and phagocytosis associated with infection occur. It has been reported that it is possible to detect an increase in the sCD14-ST concentration (WO 2009/142303).
  • sCD14-ST is produced in the process of leukocyte phagocytosing and digesting foreign microorganisms and foreign substances, it has never been considered to show a high value in a state where neutrophils are decreased. Rather, since sCD14-ST is produced from immune responder cells (leukocytes), it was thought that patients with reduced leukocytes due to chemotherapy did not show high levels even with bacterial infection (Urbonas et al., Cytokine). 62 (1): 34-37 2013).
  • An object of the present invention is to provide a method for detecting febrile neutropenia in cancer patients with high sensitivity. Another object of the present invention is to provide a method for highly sensitively detecting febrile neutropenia in a patient with neutropenia caused by administration of an anticancer drug and / or irradiation. . Another object of the present invention is to provide a method capable of selecting febrile neutropenia patients to be administered antibiotics at an appropriate timing. Furthermore, the present invention is to solve the problem of proper use of antibiotics in patients with febrile neutropenia.
  • a method for determining the timing of discontinuation of antibiotic administration a method for determining the type of antibiotic administered and / or the timing of changing the administration route, an antifungal agent and / or G- in addition to or instead of antibiotic administration It is an object of the present invention to provide a method for determining the timing for administering CSF and a method for detecting or predicting FN patients before fever.
  • the present inventor has shown that the value of the sCD14-ST concentration in the blood sample at the time of FN onset and within 72 hours from the onset of FN shows a continuously high value, particularly when the sCD14-ST concentration increases during the onset of FN (fever). Based on these findings, the inventors have invented a method for detecting febrile neutropenia with high sensitivity by measuring the sCD14-ST concentration in a blood sample derived from a cancer patient. More specifically, the present invention is as described below.
  • the present invention provides the detection method, selection method, determination method or treatment method described below.
  • (1-1) A method for detecting febrile neutropenia in a cancer patient using the sCD14-ST concentration in a blood sample derived from the cancer patient as an index.
  • (1-2) A method for detecting febrile neutropenia in a cancer patient, wherein the sCD14-ST concentration in a blood sample derived from the cancer patient is measured.
  • a method for detecting febrile neutropenia in a cancer patient comprising the following steps: 1) a step of measuring the number of neutrophils in a blood sample derived from a cancer patient, 2) determining whether the neutrophil count is less than a neutrophil count reference; 3) measuring the sCD14-ST concentration in a blood sample derived from a cancer patient; 4) a step of comparing the measured value of the sCD14-ST concentration with a reference value; and 5) a step of determining whether or not the measured value is higher than the reference value.
  • a method for detecting febrile neutropenia comprising the following steps: 1) measuring the sCD14-ST concentration in a blood sample derived from a cancer patient whose neutrophil count is less than a reference; 2) comparing the measured value of the sCD14-ST concentration with a reference value; and 3) determining whether the measured value is higher than the reference value.
  • sCD14-ST concentration in a blood sample derived from the cancer patient is measured using an anti-sCD14-ST antibody prepared using a peptide consisting of 16 amino acid residues described in SEQ ID NO: 2 as an antigen.
  • (2-1) A method for selecting a patient with febrile neutropenia to be administered with an antibiotic, using the sCD14-ST concentration in a blood sample from a patient undergoing cancer treatment as an index.
  • (2-2) A method for selecting a febrile neutropenia patient to be administered with an antibiotic in a cancer patient, comprising a step of measuring the sCD14-ST concentration in a blood sample derived from the cancer patient.
  • a method for selecting a febrile neutropenia patient to be administered with an antibiotic comprising the following steps: 1) a step of measuring the number of neutrophils in a blood sample derived from a cancer patient, 2) determining whether the neutrophil count is less than a neutrophil count reference; 3) measuring the sCD14-ST concentration in a blood sample derived from a cancer patient; 4) a step of comparing the measured value of the sCD14-ST concentration with a reference value; and 5) a step of determining whether or not the measured value is higher than the reference value.
  • the selection method according to (2-3) further comprising the following steps: 6) A step of determining that the cancer patient has febrile neutropenia when the measured value is higher than the reference value.
  • a method for selecting a patient with febrile neutropenia to be administered with an antibiotic comprising the following steps: 1) measuring the sCD14-ST concentration in a blood sample derived from a cancer patient whose neutrophil count is less than a reference; 2) comparing the measured value of the sCD14-ST concentration with a reference value; and 3) determining whether the measured value is higher than the reference value.
  • the selection method according to (2-5) further comprising the following steps: 4) A step of determining that the cancer patient has febrile neutropenia when the measured value is higher than the reference value.
  • (2-14) The above-mentioned (2-14), wherein the antibiotic is a therapeutic agent for febrile neutropenia including at least one selected from the group consisting of antibiotics, antifungal agents and G-CSF.
  • (3-1) Timing of completion of administration of the antibiotic or change of administration route in a patient with febrile neutropenia to which an antibiotic is administered, using the sCD14-ST concentration in a blood sample derived from a cancer patient as an index How to determine.
  • (3-2) Termination or administration route of the antibiotic in a patient with febrile neutropenia to which an antibiotic is administered, including the step of measuring the sCD14-ST concentration in a blood sample derived from a cancer patient How to determine the change timing.
  • a method for determining the end of administration of an antibiotic or a change in administration route in a patient with febrile neutropenia to which an antibiotic is administered including the following steps: 1) a step of measuring the number of neutrophils in a blood sample derived from a cancer patient, 2) determining whether the neutrophil count is less than a neutrophil count reference; 3) measuring the sCD14-ST concentration in a blood sample derived from a cancer patient; 4) comparing the measured value of the sCD14-ST concentration with a predetermined reference value; and 5) determining whether the measured value is less than or equal to the predetermined reference value.
  • the above antibiotics may be a therapeutic agent for febrile neutropenia containing at least one selected from the group consisting of antibiotics, antifungal agents and G-CSF. The determination method according to any one of 1) to (3-6).
  • (4-1) Using the sCD14-ST concentration in a blood sample derived from a cancer patient as an index, changing the type of the antibiotic in a patient with febrile neutropenia to which an antibiotic is administered, or A method for determining the timing of administering an antifungal agent and / or G-CSF in addition to or in place of an antibiotic agent.
  • (4-2) Changing the type of antibiotics in patients with febrile neutropenia to which antibiotics are administered or antibiotics, comprising the step of measuring the sCD14-ST concentration in a blood sample derived from a cancer patient A method for determining the timing of administration of an antifungal agent and / or G-CSF in addition to an agent or instead of an antibiotic.
  • (5-1) A method for treating a patient with febrile neutropenia by administering an antibiotic using the sCD14-ST concentration in a blood sample derived from a cancer patient as an index.
  • (5-2) A method for treating a patient with febrile neutropenia by measuring an sCD14-ST concentration in a blood sample derived from a cancer patient and administering an antibiotic.
  • a method for treating a patient with febrile neutropenia comprising the following steps: 1) a step of measuring the number of neutrophils in a blood sample derived from a cancer patient, 2) determining whether the neutrophil count is less than a neutrophil count reference; 3) measuring sCD14-ST in a blood sample derived from a cancer patient; 4) a step of selecting a cancer patient to be administered an antibiotic using the measured value of sCD14-ST in the sample as an index, and 5) a step of administering an antibiotic to the selected cancer patient.
  • the step of selecting a cancer patient to be administered an antibiotic using the measured value of sCD14-ST in the specimen as an index includes the following steps 2-1) and 2-2)
  • the antibiotic (5-8) may be a therapeutic agent for febrile neutropenia including at least one selected from the group consisting of an antibiotic, an antifungal agent and G-CSF. 1) The treatment method according to any one of (5-7).
  • the present invention also provides a kit described below.
  • (6-1) A detection kit for detecting febrile neutropenia by measuring sCD14-ST concentration in a blood sample derived from a cancer patient, and measuring the sCD14-ST concentration in a blood sample
  • a detection kit for febrile neutropenia comprising means.
  • (6-2) The febrile neutropenia detection kit according to (6-1), wherein the sCD14-ST concentration measurement means is a measurement means by an immunoassay.
  • the anti-sCD14-ST antibody is an anti-sCD14-ST antibody prepared using a peptide consisting of 16 amino acid residues set forth in SEQ ID NO: 2 as an antigen, as described in (8-1) to (8-2) above. ) Use of an anti-sCD14-ST antibody in the manufacture of a febrile neutropenia detection kit.
  • the present invention provides the use of the measured value of the sCD14-ST concentration in the blood sample described below.
  • (9-1) Use of the measured value of sCD14-ST concentration for detecting febrile neutropenia.
  • (9-2) Use of measured value of sCD14-ST concentration for selecting patients with febrile neutropenia.
  • (9-3) Use of the measured value of the sCD14-ST concentration for determining the end of administration of the antibiotic or the timing of changing the administration route in a patient with febrile neutropenia to which an antibiotic is administered.
  • (9-4) Antifungal and / or G-CSF administration in addition to or in place of antibiotics in the patients with febrile neutropenia to which antibiotics are administered Use of sCD14-ST concentration measurements to determine timing.
  • the present invention provides the use of a composition containing a therapeutic agent for febrile neutropenia as an active ingredient in the manufacture of a therapeutic agent for patients with febrile neutropenia described below.
  • 10-1 Use of a composition containing a therapeutic agent for febrile neutropenia as an active ingredient in the manufacture of a therapeutic drug for a patient with febrile neutropenia, wherein the febrile neutropenia Patients with 1) Measure the number of neutrophils in blood samples from cancer patients, 2) The neutrophil count is less than the neutrophil count reference, 3) Measure sCD14-ST concentration in blood samples from cancer patients, 4) Compare the measured value of the sCD14-ST concentration with a reference value, and 5) If the measured value is higher than the reference value, the cancer patient is a patient with febrile neutropenia Determine the use.
  • the febrile neutropenia therapeutic agent is at least one selected from the group consisting of antibiotics, antifungal agents and G-CSF.
  • a highly sensitive method for detecting febrile neutropenia can be provided.
  • a febrile neutropenia detection kit capable of detecting febrile neutropenia with high sensitivity is provided.
  • a method for determining the timing of discontinuation of antibiotics in patients with febrile neutropenia a method for determining the type of antibiotics being administered and / or the timing for changing the route of administration, in addition to or instead of antibiotics Methods are provided for determining when to administer an antifungal agent and / or G-CSF, and for detecting or predicting FN patients prior to fever.
  • these methods improve prognosis in patients with febrile neutropenia, reduce the administration of unnecessary antibiotics by optimizing the antibiotic administration period, reduce the side effects of antibiotics, or antibiotics Medical costs due to a decrease in usage can be reduced.
  • FIG. 1 is a graph showing a comparison between sCD14-ST (preceptin) concentration and PCT (procalcitonin) concentration in a specimen before, during and after FN exotherm.
  • “After fever” refers to a sample within 72 hours after fever excluding “when fever” occurs. Note that “*” in the figure indicates that there is a significant difference with respect to “before heat generation” at p ⁇ 0.001.
  • FIG. 2 is a graph showing a comparison between sCD14-ST (preceptin) concentration and PCT (procalcitonin) concentration according to the cause of FN.
  • sCD14-ST soluble CD14 antigen subtype, also known as presepsin
  • sCD14-ST is one of the molecular species of soluble CD14, characterized in that it migrates to a molecular weight of 13 ⁇ 2 kDa in SDS-PAGE under non-reducing conditions, It holds the N end of CD14.
  • sCD14-ST has an amino acid sequence that is greatly deleted on the C-terminal side compared to full-length CD14, and both are different in three-dimensional structure, and thus show different immunogenicity.
  • sCD14-ST has the property of specifically binding to an antibody prepared using a peptide consisting of 16 amino acid residues described in SEQ ID NO: 2 as an antigen. . Furthermore, sCD14-ST specifically binds to an antibody that binds to a peptide consisting of the 17th to 26th amino acids of SEQ ID NO: 3, does not bind to 3C10 antibody, and does not bind to MEM-18 antibody. In addition, any one or more of the characteristics that it has no LPS binding ability and can be obtained from human blood can be added.
  • sCD14-ST is characterized in that the amino acid sequence has the amino acid sequence of SEQ ID NO: 1 at the N-terminal sequence, and more specifically, the N-terminus is at position 1 of the amino acid sequence described in SEQ ID NO: 3, It can be identified by the feature that the C-terminal is any one of positions 59 to 90 of the amino acid sequence shown in SEQ ID NO: 3.
  • sCD14-ST is disclosed in detail in International Publication No. 2005/108429. In the present specification, sCD14-ST means human sCD14-ST unless otherwise specified.
  • the blood sample is not particularly limited, and any of whole blood, plasma, and serum may be used.
  • the blood sample may be a sample to which an anticoagulant such as EDTA, heparin, or citric acid is added after blood collection.
  • Measurement of sCD14-ST in a blood sample can be performed by a known method or a known apparatus.
  • an immunological measurement system that specifically detects sCD14-ST disclosed in International Publication No. 2004/044005 or International Publication No. 2005/108429 can be used. Specifically, it binds to an antibody (S68 antibody) prepared using a peptide consisting of 16 amino acid residues described in SEQ ID NO: 2 as an antigen and a peptide consisting of positions 17 to 26 of the amino acid sequence described in SEQ ID NO: 3.
  • S68 antibody an antibody prepared using a peptide consisting of 16 amino acid residues described in SEQ ID NO: 2 as an antigen and a peptide consisting of positions 17 to 26 of the amino acid sequence described in SEQ ID NO: 3.
  • a sandwich immunoassay system comprising an antibody or a combination with an antibody that competes with the antibody (F1106-13-3 antibody or F1031-8-3 antibody) is suitable.
  • antibodies are preferably either rat (derived) antibodies, mouse (derived) antibodies, or rabbit (derived) antibodies.
  • an antibody prepared using a peptide consisting of 16 amino acid residues described in SEQ ID NO: 2 as an antigen is a sCD14-ST specific antibody, and sCD14-ST can be detected alone.
  • An antibody prepared using a peptide consisting of 16 amino acid residues described in SEQ ID NO: 2 as an antigen exhibits an affinity of less than 10 ⁇ 9 M as a dissociation constant (Kd) for sCD14-ST.
  • the antibody prepared using a peptide consisting of 16 amino acid residues described in SEQ ID NO: 2 as an antigen is preferably a rabbit antibody or a rabbit-derived antibody.
  • the measured value of the sCD14-ST concentration in the blood sample may be a quantitative value, a semi-quantitative value, or a qualitative value.
  • the sCD14-ST concentration can be displayed in stages such as 0, 1, 2, 3 or-, +, ++, +++. Since this stage correlates with the quantitative sCD14-ST concentration, whether or not the sCD14-ST concentration is equal to or higher than a predetermined reference value depends on the correlation between the semi-quantitative step display and the quantitative sCD14-ST concentration.
  • less than the reference value may be set to a stage such as 0 or ⁇ .
  • it may be set to be negative when the value is less than the reference value and positive when the value is equal to or more than the reference value.
  • the measurement of the sCD14-ST concentration in a blood sample derived from a cancer patient may be performed over time. This is because detection, selection, or determination can be performed at a more appropriate timing by performing measurement over time.
  • antibiotics when antibiotics are administered, by selecting or determining appropriately the selection of patients to be administered, the start of administration, the change of the type of antibiotic to be administered, the change of administration route, the end of administration and / or the continuation of administration, Appropriate treatment of FN and / or rapid severity of FN can be prevented.
  • the timing of measurement should be set as appropriate, such as every day, every second day, or every third, fifth, or seventh day after the first sCD14-ST concentration measurement date after neutropenia is confirmed. That's fine.
  • the reference value is the sCD14-ST concentration in the blood sample that is set in advance to identify the population of normal persons and FN patients.
  • the reference values used in the detection method, patient selection method, timing determination method, and treatment method of the present invention may be the same, or different values may be used if necessary.
  • the same reference value may be used or different reference values may be used depending on individual patient groups, individual patients, or measurement conditions.
  • the reference value may be set to a value with good screening efficiency so that a balance between false positives and false negatives can be obtained, or set to a value at which the frequency of occurrence of febrile neutropenia begins to increase rapidly. Alternatively, it may be set to a value theoretically theoretically or may be set to a statistically determined value.
  • the reference value is obtained, for example, by calculating an average value and a standard deviation (SD) of measured values of sCD14-ST concentration in a blood sample of a medically healthy person, and a range of the average value +0.5 SD to +5 SD
  • the average value + SD, the average value + 2SD, the average value + 3SD, etc. may be set, or the average value of 5 to 95, 10 to 90, 15 to 85, or 25 to 75 percentile value may be set. May be.
  • the reference value is preferably set to the average value + 2SD or the average value + 3SD.
  • Specific numerical values include 400 pg / mL to 600 pg / mL, preferably 500 pg / mL to 600 pg / mL, and more preferably 600 pg / mL, but are not limited thereto.
  • FN febrile neutropenia
  • the final diagnosis of FN can be performed according to conventionally known diagnostic criteria. According to the FN guidelines (1998: Japan), febrile neutropenia is observed when the neutrophil count is less than 500 / ⁇ L (500 cells / mm 3 ), or less than 1000 / ⁇ L within 500 hours.
  • Febrile neutropenia (FN) is defined as a fever with an axillary temperature of 37.5 ° C or higher (oral temperature of 38 ° C or higher) that is expected to decrease to less than ⁇ L. Is done.
  • the neutrophil count can be measured using a hemocytometer.
  • the measurement frequency of the neutrophil count may be set as appropriate, such as every day or every other day from the day before or the day before the administration of the anticancer drug and / or radiation.
  • the criteria for neutrophil count in febrile neutropenia is less than 500 / ⁇ L (500 / mm 3 ), or less than 1000 / ⁇ L and expected to decrease to less than 500 / ⁇ L within 48 hours. Is defined.
  • the number of neutrophils in healthy persons is 2000 to 6000 / ⁇ L.
  • Reduced neutrophil count is due to hematopoietic diseases such as anticancer drug administration or irradiation for cancer treatment, anticancer drug administration and irradiation as pretreatment for bone marrow transplantation, or aplastic anemia. Etc.
  • Anticancer agents used for cancer treatment with reduced neutrophil count and high likelihood of FN include cisplatin, irinotecan, vinorelbine, carboplatin, paclitaxel, gemcitabine, pemetrexed, docetaxel, gefitinib, pemetrexad, etoposide, topotecan , Amrubicin, fluorouracil, capecitabine, trastuzumab, capecitabine, tegafur gimeracil oteracil potassium (TS-1), oxaliplatin, bevacizumab, elplat, panitumumab, camptothecin 11, adriamycin, cyclophosphamide, methotrexate, eribulin, eribulin Examples include vinblastine, bleomycin, rituximab, vincristine, prednisolone, ifosfamide, and dacarbacin.
  • the cancers to which these anticancer drugs are administered include non-small cell cancer, small cell cancer, head and neck cancer, stomach cancer, colorectal cancer, biliary tract cancer, breast cancer, and ovary. Cancer, bladder cancer, germ cell tumor, malignant lymphoma, sarcoma, leukemia, myelodysplastic syndrome, etc. are not particularly limited. Moreover, melphalan, busulfan, etc. are mentioned as an anticancer agent used for the pretreatment of bone marrow transplantation. The number of decreases in the number of neutrophils varies depending on the dose, administration period, administration site, etc. of the anticancer agent.
  • pre-transplantation treatment for cancer treatment and bone marrow transplantation irradiation with X-rays, electron beams, ⁇ -rays, etc. is also performed. To do.
  • bone marrow transplantation in which donor normal bone marrow cells are injected intravenously into patients with hematopoietic diseases such as leukemia and aplastic anemia, the patient's hematopoietic tissue and In order to eradicate neoplastic cells, a large amount of anticancer drug and radiation are administered, and even in these processes, the neutrophil count decreases.
  • the white blood cell count can be measured using a hemocytometer.
  • the measurement frequency of the white blood cell count may be appropriately set every day or every other day from the day before or after the administration of the anticancer drug and / or radiation.
  • the white blood cell count of a cancer patient is not particularly limited, but for example, it is preferable that the white blood cell count is reduced as compared with that of a healthy person.
  • the leukocyte count of a cancer patient is 3000 / ⁇ L (3000 / mm 3 ) or less, or 1000 / ⁇ L (1000 / mm 3 ) or less, the present invention can exert its effect. It is more preferable that the leukocyte count of the cancer patient is in the above-mentioned range.
  • the white blood cell count in a healthy person is 4000 to 8000 / ⁇ L.
  • Monocyte count can be measured using a hemocytometer.
  • the frequency of measuring the number of monocytes may be appropriately set, such as every day or every other day from the day before or after the administration of the anticancer drug and / or radiation.
  • the number of monocytes in a cancer patient is not particularly limited, but for example, it is preferable that the number of monocytes is reduced as compared with that of a healthy person.
  • the present invention can exert its effect.
  • the number of monocytes in cancer patients is more preferably in the above-described range. Note that the number of monocytes in a healthy person is 300 to 700 / ⁇ L.
  • the therapeutic agent for febrile neutropenia is not particularly limited as long as it is a drug effective for the treatment of febrile neutropenia.
  • examples thereof include antibiotics, antifungal agents, G-CSF, and mixtures thereof.
  • Antibiotics to be administered to FN patients are not particularly limited, but cefepime, tazobactam, piperacin, imipenem, silastatin, meropenem, ceftazidime, cefpirom, cefozopran, biapenem, panipenem, betamipron, dripenem, tazobactam, piperaceprin, System drugs, clindamycin and the like.
  • cefepime, tazobactam, piperacin, piperacin, imipenem, silastatin, meropenem, ceftazidime, cefpirom, cefozopran, biapenem, panipenem, betamipron which are ⁇ -lactam drugs having anti-Pseudomonas aeruginosa action as the first choice in the treatment of FN, Doripenem or the like is used.
  • FN if an antibiotic is not successful, it may be changed to another antibiotic or used in combination with another antibiotic.
  • Antibiotics are usually administered intravenously in the treatment of FN. However, if it is confirmed by laboratory findings such as antipyretic and clinical findings that antibiotics have been successful, in addition to the end of antibiotic administration, the route of oral administration May be changed.
  • G-CSF granulocyte colony-stimulating factor
  • G-CSF granulocyte colony-stimulating factor
  • N-CSF granulocyte colony-stimulating factor
  • G-CSF granulocyte colony stimulating factor
  • the recombinant human G-CSF preparation is used for neutropenia associated with cancer chemotherapy and aplastic anemia.
  • pharmaceuticals such as filgrastim (trade name Gran), Narutograstim (trade name Neuup), and Lenograstim (trade name Neutrogin).
  • Antibiotic agents, antifungal agents, and G-CSF preparations are preferably preparations having the following information. 1) A formulation for detecting and administering febrile neutropenia using sCD14-ST concentration in a blood sample derived from a cancer patient as an index. 2) A preparation for measuring the concentration of sCD14-ST in a blood sample derived from a cancer patient, and selecting and administering a patient with febrile neutropenia to be administered.
  • the above information can be provided in the package insert, interview form, brochure, instructions, etc. of the formulation, and can be provided simultaneously with the formulation or separately.
  • Detection method, selection method, determination method and treatment method 1.
  • Method for detecting febrile neutropenia The present invention provides a method for detecting febrile neutropenia using the sCD14-ST concentration in a blood sample derived from a cancer patient as an index.
  • febrile neutropenia is detected by measuring the sCD14-ST concentration in a blood sample derived from a cancer patient.
  • the sCD14-ST concentration in the blood sample continuously shows a high value (above the reference value) at the onset of FN and within 72 hours from the onset.
  • sCD14-ST concentration increases during the onset of FN (during fever)
  • febrile neutropenia can be easily detected at the time of onset, and FN It becomes possible to select an appropriate treatment based on the ability to be detected.
  • the detection method of the present invention may supplement FN patients before the final diagnosis of FN according to the above-mentioned guidelines. That is, the detection method of the present invention can be used as an auxiliary method before a doctor finally diagnoses a cancer patient as having FN.
  • a cancer patient undergoing cancer treatment may receive, but is not limited to, anticancer drug administration and / or radiation therapy and bone marrow suppression.
  • anticancer drug administration and / or radiation therapy and bone marrow suppression When the bone marrow is damaged, neutrophils, usually 2000 / mm 3 to 6000 / mm 3, decrease in the blood.
  • Cancer patients can be applied to patients who are receiving cancer treatment by administration of anticancer drugs and / or radiation and / or patients who have undergone pre-transplantation treatment of bone marrow transplantation. It may be a patient who may have decreased neutrophils. Diagnosis of febrile neutropenia may or may not be made.
  • the cancer patient may be a patient in which at least one selected from the group consisting of white blood cell count, neutrophil count and monocyte count shows a lower value than the normal value.
  • the standard for the normal value of the neutrophil count is 2000 to 6000 / ⁇ L of the neutrophil count in a healthy person.
  • the standard for the normal value of the white blood cell count is 4000 to 8000 / ⁇ L of the white blood cell count in a healthy person.
  • the standard for the normal value of the monocyte count is approximately 300 to 700 / ⁇ L of the white blood cell count in a healthy person.
  • FN In elderly patients, particularly those 65 years of age or older, or in patients receiving steroids, fever is suppressed, and the final diagnosis of FN may be delayed and become severe.
  • the detection method of the present invention since sCD14-ST concentration in a blood sample derived from a patient is measured to detect febrile neutropenia, the FN before fever is more reliably detected in such a patient.
  • FN patients can be detected or FN can be predicted by measuring sCD14-ST concentration in pre-fever FN patients. If necessary, other methods described above are used to detect FN patients. According to the detection method of the present invention, it is possible to capture a patient who will become FN in the near future, that is, a so-called FN reserve army patient, regardless of whether there is fever or no fever.
  • the detection method of the present invention may or may not be diagnosed even if the patient is diagnosed with FN.
  • the FN reserve in the present invention may be a candidate of FN or a patient suspected of FN, that is, capturing a patient of FN reserve means detecting and / or selecting a patient of FN reserve, or Predicting the onset of FN can be replaced.
  • the term “before fever” is not particularly limited as long as it is a patient before symptoms of fever are seen. If the symptoms of fever are shown later, it is preferably 7 days to 1 day before, more preferably 5 days to 1 day before, and more preferably 3 days to 1 day before, when the fever is 0 More preferably.
  • FN administration of antibiotics is often continued until antipyretic or neutrophil count of 500 / ⁇ L or more is confirmed, and administration is continued even after confirmation of antipyretic because of fear of recurrence and seriousness.
  • Antibiotics are usually administered intravenously in FN, but may be changed to oral administration after confirming antipyretic, but may be continued at the physician's discretion after changing to oral administration.
  • the antibiotic is changed, and in some cases, administration of an antifungal agent or G-CSF is considered.
  • G-CSF antifungal agent
  • it is difficult to identify the cause of FN the identification rate of the causative bacterium is low, and the fungus may be the causative bacterium.
  • the method for detecting febrile neutropenia of the present invention preferably includes a step of measuring the sCD14-ST concentration in a blood sample derived from a cancer patient.
  • a step of measuring the neutrophil count 2) a step of determining whether the neutrophil count is less than a neutrophil count reference, or 3) a sCD14-ST concentration in a blood sample derived from a cancer patient More preferably, 4) a step of comparing the measured value of the sCD14-ST concentration with a reference value, and 5) a step of determining whether or not the measured value is higher than the reference value.
  • the above steps 1) to 3) can be rephrased as “a step of measuring the sCD14-ST concentration in a blood sample derived from a cancer patient whose neutrophil count is less than the reference”.
  • the “cancer patient” is “cancer patient whose axillary temperature is measured and determined to be 37.5 ° C. or higher”, “anticancer drug administration and / or cancer treatment by radiation irradiation”.
  • a step of preparing a blood sample derived from a cancer patient may be provided before the step of measuring the sCD14-ST concentration in the blood sample derived from the cancer patient.
  • the cancer patient has febrile neutropenia.
  • the reference value used in the detection method of the present invention the above-described reference value can be used.
  • the present invention uses the sCD14-ST concentration in a blood sample derived from a cancer patient as an index, so that tumor fever caused by cancer or Among patients with febrile neutropenia, patients with febrile neutropenia for whom antibiotics etc. are to be administered, including patients who do not need antibiotics such as drug fever with anticancer drugs
  • the subject which should administer antibiotics etc. can be selected appropriately.
  • survival rate, incidence of complications, incidence of infections and side effects, functional health status of patients, patient QOL, Improvements in treatment satisfaction can be expected.
  • the method for selecting an FN patient to be administered with the antibiotic of the present invention preferably includes a step of measuring the sCD14-ST concentration in a blood sample derived from a patient.
  • the step of measuring the neutrophil count of 2) the step of determining whether or not the neutrophil count is less than the neutrophil count reference, 3) the sCD14-ST concentration in a blood sample derived from a cancer patient 4) a step of comparing the measurement value of the sCD14-ST concentration with a reference value, and 5) a step of determining whether or not the measurement value is higher than the reference value.
  • a step of measuring the sCD14-ST concentration in a blood sample derived from a patient preferably includes a step of measuring the sCD14-ST concentration in a blood sample derived from a patient.
  • the above steps 1) to 3) can be rephrased as “a step of measuring the sCD14-ST concentration in a blood sample derived from a cancer patient whose neutrophil count is less than the reference”.
  • the “cancer patient” is “a cancer patient determined to have an axillary temperature of 37.5 ° C. or higher”, “a patient receiving cancer treatment by administration of an anticancer drug and / or radiation, And / or “a cancer patient who has undergone pre-transplantation treatment of a bone marrow transplant” or “a cancer patient who is 65 years of age or older and / or is receiving steroids”.
  • This selection method can be performed in vitro.
  • this selection method can also be used as an auxiliary method before a doctor selects a patient as a medical practice.
  • a step of preparing a patient-derived blood sample may be provided before the step of measuring the sCD14-ST concentration in the patient-derived blood sample.
  • a step of determining that the patient is a patient with febrile neutropenia to which an antibiotic is administered may be included.
  • the measured value of sCD14-ST in the sample serves as an index as to whether or not it is FN
  • the measured value of the sCD14-ST concentration is compared with a predetermined reference value, so that Can be selected. More specifically, when the measured value is higher than the reference value, the patient can be selected as an FN patient to be administered with an antibiotic or the like.
  • the reference value used in the selection method of the present invention the above-described reference value can be used.
  • the present invention uses sCD14-ST concentration in a blood sample derived from a patient as an index
  • the present invention provides a method for determining the end of administration of an antibiotic or the timing of changing the administration route in a patient with febrile neutropenia to which an antibiotic is administered.
  • this determination method it is possible to determine an appropriate antibiotic end or administration route change timing in an FN patient to whom an antibiotic is administered, using the sCD14-ST concentration in a blood sample derived from the patient as an index.
  • treatment with antibiotics is completed at an appropriate time, or appropriate administration routes such as switching from intravenous administration to oral administration are changed, and unnecessary antibiotics are not administered.
  • the method for determining the end of administration of the antibiotic or the timing of changing the administration route in the FN patient to which the antibiotic of the present invention is administered comprises a step of measuring the sCD14-ST concentration in the blood sample derived from the patient, 1) a step of measuring a neutrophil count in a blood sample derived from a cancer patient, 2) a step of determining whether the neutrophil count is less than a neutrophil count reference, or 3) a patient-derived count
  • a step of measuring the sCD14-ST concentration in the blood sample 4) a step of comparing the measured value of the sCD14-ST concentration with a reference value; and 5) determining whether the measured value is less than or equal to the reference value
  • the method further comprises 6) including the step of determining the end of administration of the antibiotic to the patient when the measured value is less than or equal to the reference value, or 7) the measured value is the reference value.
  • the reference value used in the method for determining the end of administration of the antibiotic of the present invention or the timing of changing the administration route may be any value that can confirm that the antibiotic is successful.
  • a value such as 1/2, 1/5, or 1/10 of the measured value of sCD14-ST measured from before antibiotic administration to 24 hours after administration can be set as the reference value.
  • the above-mentioned reference value can be used.
  • the measurement of sCD14-ST after the onset of FN can be appropriately set and measured, for example, within 5 days, within 7 days, within 14 days, etc. from the start of antibiotic administration.
  • the reference value of these sCD14-ST and the measurement time from the start of antibiotic administration are not limited to the above.
  • the method for determining the end timing of administration of the antibiotic of the present invention is the administration of the antibiotic to the patient when the measured value is lower than the reference value as described in 4-1).
  • Method for selecting febrile neutropenia patient who finishes administration of antibiotic by using "step for selecting said patient as patient who finishes administration of antibiotic” instead of "step of determining termination”
  • the method for determining the administration route change timing of the antibiotic of the present invention is described in “7. When the measured value is not more than the reference value, the administration route change of the antibiotic for the patient is determined.
  • Method for determining the timing of administration of an antifungal agent and / or G-CSF in addition to or in place of an antibiotic agent in a febrile neutropenia patient to whom an antibiotic agent is administered The invention relates to a change in the type of antibiotics in patients with febrile neutropenia to which antibiotics are administered, or in addition to or in addition to antibiotics, using sCD14-ST concentration in a blood sample derived from a patient as an index.
  • Provided is a method for determining the timing of administration of an antifungal agent and / or G-CSF instead of an agent.
  • the sCD14-ST concentration in the blood sample derived from the patient is used as an index to change the appropriate antibiotic type in FN patients to whom antibiotics are administered, or in addition to or in addition to antibiotics.
  • the timing of antifungal and / or G-CSF administration can be determined.
  • the type of antibiotic is changed at an appropriate time, or an appropriate antifungal agent and / or G-CSF is added to or replaced with an antibiotic, and unnecessary antibiotics are not administered.
  • administration of appropriate therapeutic agents improve survival rate, incidence of complications, incidence of infections and side effects, functional health of patients, patient QOL, treatment satisfaction, etc. You can expect.
  • the method for determining the timing of administration of an antifungal agent and / or G-CSF in addition to or in place of an antibiotic agent in an FN patient to whom the antibiotic of the present invention is administered includes a step of measuring the sCD14-ST concentration in a blood sample derived from 1) a step of measuring the number of neutrophils in a blood sample derived from a cancer patient, and 2) the number of neutrophils is neutrophil.
  • the method for determining the timing of changing the type of antibiotic according to the present invention is described in the above 6) “When the measured value is equal to or higher than the reference value, the type change of the antibiotic for the patient is determined.
  • the step of ⁇ to perform the step of selecting the patient as a patient whose type of antibiotic is to be changed ''
  • the method for selecting a patient with febrile neutropenia to change the type of antibiotic , "By selecting the patient as a patient who does not change the type of antibiotic"
  • the method for determining the administration timing of an antifungal agent and / or G-CSF in addition to or in place of the antibiotic of the present invention is described in 7) “The measured value is not less than the reference value”. Instead of the step of determining the administration of an antifungal agent and / or G-CSF in addition to or in place of the antibiotic for the patient.
  • “selecting the patient as a patient who does not receive an antifungal agent and / or G-CSF in addition to or in place of the antibiotic” In Rukoto it can be rephrased in addition to or antifungal agent and / or G-CSF selection method of febrile neutropenia patients not administered on behalf of the antibiotic in antibiotic.
  • This determination method can be performed in vitro. This determination method can also be used as an auxiliary method before the doctor determines the administration timing as a medical practice.
  • the present invention provides a method for treating FN.
  • the treatment method of the present invention selects FN patients who need to remove bacteria with antibiotics in addition to normal treatment, using as an index the number of neutrophils in blood samples derived from cancer patients and the measured value of sCD14-ST.
  • a method of treating FN by administering an antibiotic to a selected patient Specifically, as described in 2. above. An FN patient to be administered an antibiotic is selected by the method described in the embodiment, and the antibiotic is administered to the selected patient. In addition, the 3. 3.
  • Kit comprising sCD14-ST concentration measurement means in blood sample
  • the present invention also provides a febrile neutropenia detection kit comprising a sCD14-ST concentration measurement means in a blood sample.
  • the detection kit of the present invention is preferably an immunological assay kit (Immunoassay Kit).
  • an antibody prepared using a peptide consisting of 16 amino acid residues described in SEQ ID NO: 2 as an antigen
  • multiwell plate and spectrophotometer It may include at least one selected from the group consisting of a total.
  • This kit can preferably measure the sCD14-ST concentration in a blood sample by a sandwich immunoassay using a combination of S68 antibody and F1106-13-3 antibody or F1031-8-3 antibody.
  • the kit can measure the sCD14-ST concentration in a blood sample by a sandwich immunoassay using a combination of S68 antibody and F1106-13-3 antibody.
  • the detection kit include, in addition to antibodies that can be used for detection of sCD14-ST such as S68 antibody and F1106-13-3 antibody, reagents or instruments necessary for sandwich immunoassay (immunological assay kit) , And reagents or instruments necessary for measuring the concentration of sCD14-ST in a blood sample, but not limited thereto, the detection kit includes other necessary reagents, samples, instruments, and fixtures. Etc. can also be included.
  • antibodies that can be used for detection of sCD14-ST include antibodies having the same binding activity to sCD14-ST as the above-described S68 antibody, F1106-13-3 antibody, or F1031-8-3 antibody.
  • the method for evaluating the binding activity is not particularly limited, and a known method can be used.
  • kits comprising means for measuring sCD14-ST concentration to detect febrile neutropenia
  • the present invention detects FN
  • Kit including a device for measuring the concentration of sCD14-ST in a blood sample” above, and / or Recombinant soluble CD14 fragment is used.
  • the method of the present invention may be fatal due to side effects (such as opportunistic infections such as MRSA infection) caused by therapeutic agents having an immunosuppressive effect. Usefulness is high if it can be done at an early stage, such as in determining the therapeutic effect.
  • Example 1 Sample collection In hospitalized patients who developed FN, received written consent, received chemotherapy such as anticancer drugs and / or bone marrow transplantation including pre-transplantation treatment, From 75 FN events in 43 patients with acute spinal leukemia, malignant lymphoma, etc., 114 peripheral blood samples were collected before FN onset and within 72 hours after FN onset. The above samples include cases in which FN occurs multiple times in the same patient. Serum was separated by centrifuging the collected peripheral blood at 4 ° C. (3000 rpm, 20 minutes). The separated plasma was stored frozen at ⁇ 20 ° C. and subjected to sCD14-ST and procalcitonin (PCT) measurement.
  • PCT procalcitonin
  • the FN event was determined according to the FN clinical practice guidelines established in 2012 by the Japanese Society of Clinical Oncology. That is, it is judged that the neutrophil count is less than 500 / ⁇ L, or less than 1000 / ⁇ L, and may be less than 500 / ⁇ L within 48 hours, and patients whose armpit temperature is 37.5 ° C. or higher are treated as FN Defined as onset. It should be noted that as a criterion for determining the FN event, it is not questioned whether antibiotics, antifungal agents, and antiviral agents are prophylactically administered.
  • Example 2 Measurement of neutrophil count and measurement of sCD14-ST concentration
  • the neutrophil count was measured using a hemocytometer using a leukocyte count and a neutrophil contained in the leukocyte fraction (striated nucleus). And the ratio of the sphere and the segmented nucleus cell).
  • the sCD14-ST concentration in the specimen was measured using a sandwich ELISA system using the F1106-13-3 antibody and the S68 antibody described in WO 2004/044005.
  • As the sCD14-ST protein standard rsCD14-ST described in International Publication No. 2005/108429 was used.
  • PCT concentration in a specimen was determined using LBA-, using a measurement reagent Mutaswaco Brahms PCT (Wako Pure Chemical Industries) and a fully automatic fluorescence immunoassay device Mutus Wako i30 (Wako Pure Chemical Industries). It was measured by the EATA method. That is, after reacting PCT in a sample with a DNA-labeled anti-calcitonin antibody and a fluorescent-labeled anti-catacalcin antibody, the formed immune complex was separated by gel electrophoresis, and the PCT concentration was measured by fluorescence detection.
  • Example 4 Comparison of sCD14-ST Concentration and PCT Concentration in FN Patients Among 75 FN events, non-pyrogenic specimen (12 cases), FN onset specimen (sCD14-ST is 25 cases, PCT is 24 cases) Example) and the average value of sCD14-ST concentration and PCT concentration in samples (75 cases) within 72 hours after the onset of FN were calculated.
  • the results are shown in FIG. 1 as “non-fever” for the non-pyrogenic specimen, “fever” for the specimen at the onset of FN, and “after fever” for the specimen within 72 hours after the onset of FN.
  • FIG. 1 The results are shown in FIG. 1 as “non-fever” for the non-pyrogenic specimen, “fever” for the specimen at the onset of FN, and “after fever” for the specimen within 72 hours after the onset of FN.
  • the average values of the PCT concentrations of “before heat generation”, “at the time of heat generation”, and “after heat generation” are 0.07 ng / mL, 0.12 ng / mL and 0.58 ng / mL, respectively, and the sCD14-ST concentration Were 436.28 pg / mL, 789.55 pg / mL, and 872.09 pg / mL, respectively.
  • samples at the onset of FN are excluded from samples within 72 hours after the onset of FN. There was no significant increase in PCT concentration between before and at the time of fever, whereas sCD14-ST showed a significant increase.
  • Example 5 Comparison of sCD14-ST Concentration and PCT Concentration in FN Patients Administered with Antibiotics (1) PCT Concentration after Fever and sCD14-ST Concentration in FN Event and Group Unsuccessful Analyze it in two parts. As a result, there is no difference in the PCT concentration between the two groups, but the sCD14-ST concentration is high in the group in which the antibiotic was not successful.
  • the determination of whether or not the antibiotic was successful was determined by using laboratory findings such as body temperature and clinical findings as an index after administering the antibiotic for several days.
  • Example 6 Comparison of sCD14-ST concentration and PCT concentration in cause-specific FN patients
  • the PCT concentration and sCD14-ST concentration after fever in 75 cases of FN events were tabulated and analyzed by cause.
  • the results are shown in FIG.
  • the mean PCT concentrations of “unknown fever”, “local infection” and “bacteremia / sepsis” are 0.41 ng / mL, 0.25 ng / mL and 1.68 ng / mL, respectively.
  • -Average values of ST concentrations were 809.42 pg / mL, 899.19 pg / mL and 964.95 pg / mL, respectively. From the results shown in FIG.
  • PCT has a low positive rate for unknown fever, and in this example, only 5 specimens showed a value of 0.5 ng / mL or more in 29 cases of unknown fever.
  • sCD14-ST showed a value of 600 pg / mL or more in 23 cases among 29 cases of unknown heat, and it was revealed that sCD14-ST was excellent in FN detection power.
  • Example 7 Time-dependent change of sCD14-ST concentration and PCT concentration in antibiotic-administered FN patients
  • the number of neutrophils is less than 500 / ⁇ L, or the number of neutrophils is less than 1000 / ⁇ L and within 500 hours within 500 hours
  • Blood is collected over time from a patient administered with an anticancer drug that has been determined to be less than the blood concentration, and the blood sCD14-ST concentration is compared with the PCT concentration.
  • the sCD14-ST concentration increases prior to or simultaneously with fever, but no significant change in PCT concentration is observed.
  • SCD14-ST decreases in patients who have succeeded with antibiotics, but remains high in patients who have not responded to antibiotics. The above results indicate that sCD14-ST is not only useful for determining the start of antibiotic administration, but also for early determination of antibiotic changes.
  • Example 8 Comparison of sCD14-ST concentration and PCT concentration in steroid-administered neutropenia
  • a steroid and an anticancer agent were administered, and the neutrophil count was less than 500 / ⁇ L, or the neutrophil count was 1000.
  • Blood is collected over time from a patient who is determined to be less than 500 / ⁇ L within 48 hours, and the blood sCD14-ST concentration is compared with the PCT concentration. Although the sCD14-ST concentration sometimes increases even when no fever is observed, no increase in the PCT concentration is observed even in such patients. In such cases, bacterial infection is also demonstrated in blood cultures.
  • sCD14-ST can sensitively detect essential changes in the body that cause fever, so that it is possible to decide empirical antibiotic administration.
  • Example 9 Optimization of antibiotic administration period in patients with febrile neutropenia using sCD14-ST as an index.
  • Patients who have been diagnosed with febrile neutropenia and who have been subject to antibiotic administration are usually The sCD14-ST group is divided into a control group that performs antibiotic treatment and an sCD14-ST group that performs antibiotic treatment using sCD14-ST as an index.
  • administration of antibiotics is terminated according to the judgment of a normal doctor.
  • the sCD14-ST group the sCD14-ST concentration is measured over time (eg, every day after the start of antibiotic administration), and the administration of the antibiotic is terminated based on the judgment of the doctor.
  • Patient findings refer to laboratory findings such as body temperature and clinical findings, but are preferably findings related to febrile neutropenia.
  • self-evaluation of the patient's health condition (VAS, QOL questionnaire, etc.) and sCD14-ST measurement value may be added.
  • VAS patient's health condition
  • sCD14-ST self-evaluation of the patient's health condition
  • sCD14-ST measurement value may be added.
  • the FN recurrence rate is low in patients who have completed antibiotic treatment with sCD14-ST as an index, or there is no difference in the symptom improvement status between the two groups, but antibiotic administration with sCD14-ST as an index In the group that finished the treatment, the antibiotic administration period was shorter.
  • the timing of ending antibiotic administration can be determined appropriately, and the appropriate antibiotic administration period can be determined without impairing the safety and effectiveness of antibiotic treatment. Can be determined.
  • Example 10 Measurement of white blood cell count, neutrophil count and monocyte count and detection of FN
  • 25 cases classified as “samples at the onset of FN" in Example 4 the white blood cell count, neutrophil count, monocyte count Confirmed the effect of sCD14-ST production.
  • the average value of sCD14-ST concentration in 25 cases is 789.55 pg / mL
  • the average value of white blood cell count, neutrophil count and monocyte count in 25 cases is 1348 / ⁇ L, 280 / ⁇ L and 107 / ⁇ L, respectively.
  • Met Met.
  • the average value of sCD14-ST concentration in these 5 cases was 854.06 pg / ml, compared to the average value of the entire 25 cases There was no big difference.
  • 6 cases had 0 neutrophil count at the time of FN onset, and the average value of sCD14-ST concentration in these 6 cases was 838.60 pg / ml, There was no big difference compared to the value.
  • the number of monocytes was measured for 25 cases. The measurement of the number of monocytes was calculated from the ratio between the white blood cell count and the monocytes contained in the white blood cell fraction using a hemocytometer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode de détection de la neutropénie fébrile chez un patient cancéreux, dans laquelle la concentration de sCD14-ST dans un échantillon sanguin prélevé sur le patient cancéreux est utilisée en tant qu'indice ; ainsi qu'une méthode qui permet de sélectionner un patient atteint de neutropénie fébrile auquel un antibiotique doit être administré, dans laquelle ladite concentration de sCD14-ST est utilisée en tant qu'indice.
PCT/JP2014/061897 2013-04-30 2014-04-28 Diagnostic de la neutropénie fébrile par mesure de la présepsine WO2014178383A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015514852A JP6445969B2 (ja) 2013-04-30 2014-04-28 プレセプシン測定による発熱性好中球減少症の診断

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013-095554 2013-04-30
JP2013095554 2013-04-30

Publications (1)

Publication Number Publication Date
WO2014178383A1 true WO2014178383A1 (fr) 2014-11-06

Family

ID=51843508

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/061897 WO2014178383A1 (fr) 2013-04-30 2014-04-28 Diagnostic de la neutropénie fébrile par mesure de la présepsine

Country Status (2)

Country Link
JP (1) JP6445969B2 (fr)
WO (1) WO2014178383A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035930B1 (ru) * 2019-03-11 2020-09-02 Государственное учреждение "Минский научно-практический центр хирургии, трансплантологии и гематологии" Способ диагностики инвазивных грибковых инфекций у пациента с опухолевым заболеванием кроветворной ткани

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044005A1 (fr) * 2002-11-12 2004-05-27 Mochida Pharmaceutical Co., Ltd. Trousse d'analyse de cd14 humain de faible poids moleculaire et anticorps associe
US20120238460A1 (en) * 2007-11-08 2012-09-20 Dana-Farber Cancer Institute, Inc. Rantes levels as a diagnostic and therapeutic for acute graft versus host disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044005A1 (fr) * 2002-11-12 2004-05-27 Mochida Pharmaceutical Co., Ltd. Trousse d'analyse de cd14 humain de faible poids moleculaire et anticorps associe
US20120238460A1 (en) * 2007-11-08 2012-09-20 Dana-Farber Cancer Institute, Inc. Rantes levels as a diagnostic and therapeutic for acute graft versus host disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KOH, HIDEO ET AL.: "Diagnostic Value Of Serum Level Of Soluble CD 14-Subtype In Febrile Neutropenia In Patients With Hematologic Disorders", BLOOD, vol. 122, no. 21, 15 November 2013 (2013-11-15), pages 4718 *
MINORU YOSHIDA: "Rinshoi ga Shitte Okubeki Kokin'yaku no Tsukaikata III Tokushu Byotai Tokushu Bumon deno Tsukaikata Kochukyu Genshoji no Hatsunetsu", SHINDAN TO CHIRYO, vol. 96, no. 1, 2008, pages 103 - 109 *
URBONAS, VINCAS ET AL.: "The predictive value of soluble biomarkers ( CD 14 subtype, interleukin-2 receptor, human leucocyte antigen-G) and procalcitonin in the detection of bacteremia and sepsis in pediatric oncology patients with chemotherapy-induced febrile neutropenia", CYTOKINE, vol. 62, no. 1, 17 March 2013 (2013-03-17), pages 34 - 37 *
WONG, MICHELLE ET AL.: "Microbial Translocation Contribute to Febrile Episodes in Adults with Chemotherapy-Induced Neutropenia", PLOS ONE, vol. 8, no. 7, 16 July 2013 (2013-07-16), pages E68056 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035930B1 (ru) * 2019-03-11 2020-09-02 Государственное учреждение "Минский научно-практический центр хирургии, трансплантологии и гематологии" Способ диагностики инвазивных грибковых инфекций у пациента с опухолевым заболеванием кроветворной ткани

Also Published As

Publication number Publication date
JPWO2014178383A1 (ja) 2017-02-23
JP6445969B2 (ja) 2018-12-26

Similar Documents

Publication Publication Date Title
Scott et al. S100A8/A9 regulates CD11b expression and neutrophil recruitment during chronic tuberculosis
Gasecka et al. Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel
JP6055764B2 (ja) 乳癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
US10054585B2 (en) Diagnosis of respiratory tract infectious disease using urine specimens
Pohlen et al. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B‐ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B‐cell lymphoma
US20160161506A1 (en) Diagnosis of respiratory tract infectious disease using blood specimens
JP6445969B2 (ja) プレセプシン測定による発熱性好中球減少症の診断
JP6450594B2 (ja) プレセプシン測定による炎症性腸疾患の診断
EP3578983A1 (fr) Procédé de détection du cancer du pancréas
JP6445840B2 (ja) プレセプシン測定による血球貪食症候群の検出
AU2014252894A1 (en) CCL22 and CCL17 cancer biomarkers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14791599

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015514852

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14791599

Country of ref document: EP

Kind code of ref document: A1